Gene editing therapy for bubble boy disease has a money back guarantee

ADA-SCID, commonly known as bubble boy disease, is a immune system disease caused by a mutation in the adenosine deaminase gene. It is commonly treated by bone marrow transplantion from a donor. Now, pharmaceutical company GlaxoSmithKline has developed an new gene editing therapy called Strimvelis, which uses retroviral gene editing to insert a healthy gene into a patient’s own cells, with a money back guarantee if it doesn’t work. Read more about the implications of this in a CNN article by Susan Scutti, featuring commentary by our PI, Dr. Hoggatt:

Learn More.

What are your 2019 research resolutions?

Mass General Research Resolutions

MGH researchers explain their fields of study and share their New Years resolutions in this thoughtful piece featuring Drs. Fatima Cody Stanford, Nitya Jain, Shannon Stott, Helen Riess, Sareh Parangi, Pike See Cheah, Guisy Romano-Clarke, and our very own PI, Jonathan Hoggatt. This year, the Hoggatt lab hopes to better understand hematopoietic stem cell heterogeneity to enhance bone marrow transplantation.

Learn More.